Therapeutical Vaccines
DGRA-Memberworkshop November 27, 2012
Wissenschaftszentrum Bonn,
Ahrstraße 45, 53175 Bonn

10.00 a.m. – 4.30 p.m.

Moderation: Dr. Bettina Klug

Speakers: Dr. Bridget Heelan, MHRA, London
Dr. Matthias Giese, IMV Heidelberg
Dr. Nathalie Morgensztejn, ANSM France
Dr. MD Patrick Therasse, GlaxoSmithKline Biologicals
Prof. Dr. Jürgen Rockstroh, Uniklinik Bonn
Dr. Matthias Schroff, Mologen AG, Berlin

Programme:

10.00 a.m.  I.  Breaking tolerance, pre-requisite for the development of therapeutic vaccines - new approaches in vaccine development.
             How we meet regulatory requirements
             Point out the immunological challenge with therapeutic vaccines
             • “autologous” antigen – breaking tolerance
             • Autoimmunity
             • Role of innate immune response
             • Role of cellular immune response

Immune modulators
• Own platform technology

Dr. Matthias Schroff, Mologen AG

10.45 – 11.15 coffee break
11.15 a.m.  II. Approved veterinary vaccines paving the way for the development of human therapeutic vaccines?

Current status of approved therapeutic vaccines in the veterinary field

Equine Arteritis Virus-Vaccine
- Disease characteristic and vaccine design
- Impact for human medicine

Canine Melanoma Vaccine
- Biology of canine melanoma
- The vaccine
- Impact for human medicines

Dr. Matthias Giese, Institute for Molecular Vaccines

12.00  III. Clinical development of therapeutic cancer vaccines

Clinical development of a human anticancer vaccine
(Presentation will be tailored upon the request)

PhD MD Patrick Therasse, Vice President GlaxoSmithKline Biologicals

12.45-1.45 p.m. lunch break

1.45  IV. Challenges in the clinical development of cancer vaccines – Regulators perspective

Translation from non-clinical to clinical data - what are the challenges
- Impact of the natural course of the disease on the clinical development
- What can we expect from a tumour vaccine

Clinical trials (EMA and FDA guidelines)
- Patients populations
- Endpoints

Dr. Bridget Heelan, MHRA

2.30 – 3.00 p.m. coffee break

3.00 – 3.45  V. HIV Therapeutic Vaccine Shows Signs of Promise

Vacc-4X
- Objectives of a therapeutic HIV vaccines
- Preliminary Results (presented in Bangkok)

Prof. Dr. Jürgen Rockstroh, Uniklinik Bonn

3.45 – 4.30  VI. The place of a therapeutic HIC vaccine in the toolbox for HIV treatments

- Goals to archive with the vaccine
- Safety and efficacy requirements
- Clinical trial issues – how to select the clinical trial population

Dr. Nathalie Morgensztejn, National Agency of Medicine and Health Product Safety

Further information p.t.o.
Date:
Tuesday, November 27, 2012
Start:  10.00 a.m.
End: around 4:30 p.m.

Venue:
Wissenschaftszentrum Bonn, Ahrstraße 45, D-53175 Bonn, phone: +49 228/302-0

Participation fees:
For DGRA members and M.D.R.A. students course XIV: € 220

The Casino is open for lunch (not included)

Cancellation terms:
Up to two weeks before the first day of the conference (13-Nov-12): € 50; up to one week before the first day of the conference (20-Nov-12): 50% of fee; late cancellations: full conference fee if a substitute participant (DGRA member) cannot be put forward.

In the event of cancellation by the organizer, any fees already paid will be fully reimbursed.

Conference language:
English

Room reservation:
A limited number of rooms are available for participants at special rates in the hotels listed below. When making reservations (up to Nov 9) please refer to DGRA.

- Sternhotel, Bonn-Innenstadt
  Phone: +49 - 228/7 26 70

- Villa Godesberg, Bonn-Bad Godesberg
  Phone: +49 - 228/83 00 60

More available rooms for direct booking
www.bonnhotels.de (incl. public transport), www.hrs.de

Registration:
DGRA members are requested to use the form at www.dgra.de or contact us at info@dgra.de

DGRA-office
Adenauerallee 15
D-53111 Bonn
Fax: +49 228/368 26 47
E-mail: info@dgra.de